Close menu




December 15th, 2021 | 11:35 CET

Valneva, XPhyto Therapeutics, Pfizer - Corona is far from defeated

  • Biotechnology
Photo credits: pixabay.com

In an interview, new Health Minister Karl Lauterbach said, "We will not succeed in defeating Corona completely in the foreseeable period." By period, he probably means his term, which is four years. Thus, the hope that arose in the middle of the year related to a quick end by vaccination seems to have been dashed. The new Omicron variant cannot yet be fully assessed. It is causing uncertainty on the stock markets, which puts renewed pressure on companies that have already suffered from Corona. On the other hand, there are also the profiteers who are fighting Corona. Today we analyze three of these potential profiteers.

time to read: 4 minutes | Author: Armin Schulz
ISIN: VALNEVA SE EO -_15 | FR0004056851 , XPHYTO THERAPEUTICS | CA98421R1055 , PFIZER INC. DL-_05 | US7170811035

Table of contents:


    Valneva - Poor study results weigh on shares

    Vaccine manufacturers are the biggest winners from the Corona pandemic. Valneva is betting on a so-called dead vaccine against the virus. This conventional vaccination method could make it easier to convince vaccination skeptics to vaccinate. The approach with dead vaccines has been practiced for decades and usually causes only minor side effects. The EU already secured 60 million doses of the VLA2001 vaccine in November, although it is still in phase 3 clinical trials.

    On December 2, there was a setback when a Southampton study was published that evaluated seven different vaccines for safety and efficacy as boosters. There were no limitations on safety; however, for efficacy, the vaccine did not meet predefined criteria for a minimal clinically meaningful difference in people vaccinated with two doses of Pfizer-BioNTech. It remains to be seen whether the EU will approve the vaccine.

    The Company responded immediately and issued a press release. It pointed out that the participants had received the booster vaccination relatively early, and thus the results had been negatively affected. The Company itself will set up a heterologous study and administer the booster vaccine only after 6 months. Nevertheless, the news came too late for the stock. It fell by more than 20% after the study announcement. At its peak, the share price fell from EUR 27.80 to EUR 19.60. A comprehensive analysis of the Company can also be found at researchanalyst.com.

    XPhyto Therapeutics - Acquires 3a-diagnostics

    Since rapid tests are free of charge again in Germany, demand increases significantly. Here, XPhyto Therapeutics comes into play. Together with 3a-diagnostics GmbH, XPhyto Therapeutics has developed a PCR test that delivers results within about 25 minutes after sample collection. Thus, this test has a clear time advantage over conventional PCR tests, which require 4 to 6 hours in the laboratory alone to obtain a result. Therefore, it is ideal for all areas of application that require rapid results, such as airports or hospitals that need a quick diagnosis for accident victims.

    On November 29, the Company closed a private placement of 7 million Canadian dollars (CAD). CAD 4.5 million was raised through the issuance of shares at CAD 1 each. CAD 2.5 million was raised through a convertible debenture, which is convertible into shares at CAD 1.25 and bears interest at 8%. The money was used to finance the acquisition of 3a-diagnostics, which was announced on December 6. Peter Damouni expressed his satisfaction with the strategic acquisition, saying, "The integration of a highly innovative European biosensor development company puts XPhyto at the forefront of the point-of-care rapid testing industry, an explosively developing and technology-driven sector." 3a-diagnostics additionally has a pipeline of biosensor screening tests for a wide variety of viral diseases.

    In addition to diagnostics, two other business units exist at XPhyto. First, the Company develops innovative drug delivery systems. Secondly, the Company is involved in psychedelic agents that could combat mental illness. More detailed information about the different business areas can be found in the analysis on researchanalyst.com. Currently, the focus is on the diagnostics area, where demand is now highest. The share has been in a downward trend since mid-February and is presently quoted at CAD 1.10. In February, the price was still at CAD 3.45. As soon as the Company can report larger orders for PCR tests, opportunities will arise.

    Pfizer - Acquisition of Arena Pharmaceuticals

    For Pfizer, the collaboration with BioNTech has more than paid off. The German Company was the first to present an effective vaccine called Comirnaty against the Coronavirus. For Pfizer, the active ingredient is an absolute goldmine. More than 50% of sales are attributable to the vaccine. Now that more booster vaccinations are needed, and the first children between the ages of 5 and 11 are being vaccinated, it can be assumed that this trend will continue for the time being. Not only have sales climbed significantly but so have profits.

    The profits were invested in the acquisition of Arena Pharmaceuticals on December 13. The deal cost the Group USD 6.7 billion. It paid a premium of over 100% to Friday's closing price. Arena's expertise in inflammation and immunology ideally complements Pfizer's portfolio. The drug Etrasimod, a potential blockbuster, is in a phase 3 trial, which is very promising. The sales potential is estimated at over USD 1 billion in a fast-growing market.

    Despite the business doing well, the stock has not performed nearly as well as BioNTech. Since the low in the first Corona wave in March 2020 of USD 26.43, the share has more than doubled and is currently trading at USD 55.20. In the coming quarter, the Company will pay a dividend of USD 0.40. Calculated over the year, the dividend is about 2.9%. The takeover may give rise to new fantasies, but one should wait for a setback before entering the market.


    All three companies can profit enormously from the Corona Crisis if the tests are successful and marketed accordingly. Valneva is waiting for EU approval and can then start shipping. XPhyto Therapeutics has three mainstays. At the moment, the rapid PCR tests are most marketable. The share should pick up as soon as a larger order comes in. Pfizer is a well-known pharmaceutical company that will make its way even without Corona. Nevertheless, profits are rising here as well during Corona.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read